In December 2024, the FDA approved Tirzepatide (Zepbound) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This marks a significant milestone as Tirzepatide is the first prescription drug approved for OSA. Initially launched in 2023 for obesity-related conditions, its potent weight loss effects…
Read More